MX2021009667A - Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. - Google Patents

Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.

Info

Publication number
MX2021009667A
MX2021009667A MX2021009667A MX2021009667A MX2021009667A MX 2021009667 A MX2021009667 A MX 2021009667A MX 2021009667 A MX2021009667 A MX 2021009667A MX 2021009667 A MX2021009667 A MX 2021009667A MX 2021009667 A MX2021009667 A MX 2021009667A
Authority
MX
Mexico
Prior art keywords
thioeno
pyridin
familial dysautonomia
amine compounds
treating familial
Prior art date
Application number
MX2021009667A
Other languages
English (en)
Inventor
Amal Dakka
Jana Narasimhan
Xiaoyan Zhang
Nanjing Zhang
Gary Mitchell Karp
Nikolai A Naryshkin
Michael A Arnold
Tom Tuan Luong
Jiashi Wang
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021009667A publication Critical patent/MX2021009667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a compuestos de fórmula (I) útiles para mejorar el corte y empalme de pre-ARNm en una célula. En particular, otro aspecto de la presente descripción se refiere a compuestos de tieno[3,2-b]piridina sustituidos, formas y composiciones farmacéuticas de los mismos y a métodos de uso para tratar o mejorar la disautonomía familiar.
MX2021009667A 2019-02-13 2020-02-10 Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. MX2021009667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805283P 2019-02-13 2019-02-13
PCT/US2020/017430 WO2020167628A1 (en) 2019-02-13 2020-02-10 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
MX2021009667A true MX2021009667A (es) 2021-12-10

Family

ID=69960696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009667A MX2021009667A (es) 2019-02-13 2020-02-10 Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.

Country Status (16)

Country Link
US (1) US20220135586A1 (es)
EP (1) EP3924049A1 (es)
JP (1) JP2022520822A (es)
KR (1) KR20210137040A (es)
CN (1) CN113795304A (es)
AU (1) AU2020222881A1 (es)
BR (1) BR112021015853A2 (es)
CA (1) CA3129067A1 (es)
CL (1) CL2021002137A1 (es)
CO (1) CO2021010598A2 (es)
EA (1) EA202192170A1 (es)
IL (1) IL285399A (es)
MX (1) MX2021009667A (es)
PE (1) PE20220139A1 (es)
SG (1) SG11202108519TA (es)
WO (1) WO2020167628A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013856A (es) 2020-05-13 2023-04-05 Chdi Foundation Inc Moduladores htt para tratar la enfermedad de huntington.
EP4277626A1 (en) * 2021-01-14 2023-11-22 Georgetown University Usp13 inhibitors and methods of use thereof
CN112920053B (zh) * 2021-02-01 2022-07-01 暨明医药科技（苏州）有限公司 一种手性α-甲基芳乙胺的制备方法
US20240043444A1 (en) * 2021-02-05 2024-02-08 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
US20240051968A1 (en) * 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
TW202313623A (zh) 2021-06-03 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其藥用用途
CA3231007A1 (en) * 2021-09-07 2023-03-16 Scott J. Barraza Methods for treating neurogenerative diseases
WO2023081860A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
WO2023212239A1 (en) 2022-04-27 2023-11-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023220435A1 (en) 2022-05-12 2023-11-16 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023250316A1 (en) * 2022-06-22 2023-12-28 Ptc Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3
WO2024036143A2 (en) * 2022-08-09 2024-02-15 Ptc Therapeutics, Inc. Methods for modulating rna splicing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020829B1 (en) * 2013-07-12 2021-11-17 Kyoto University Pharmaceutical composition capable of inhibiting abnormal splicing causative of onset or progress of a genetic disease
PT3244891T (pt) * 2015-01-16 2022-10-20 Massachusetts Gen Hospital Compostos para melhorar o splicing do arnm

Also Published As

Publication number Publication date
CO2021010598A2 (es) 2021-08-30
EA202192170A1 (ru) 2021-11-15
CL2021002137A1 (es) 2022-02-25
AU2020222881A1 (en) 2021-09-09
BR112021015853A2 (pt) 2021-10-05
WO2020167628A1 (en) 2020-08-20
PE20220139A1 (es) 2022-01-27
EP3924049A1 (en) 2021-12-22
IL285399A (en) 2021-09-30
KR20210137040A (ko) 2021-11-17
US20220135586A1 (en) 2022-05-05
CN113795304A (zh) 2021-12-14
SG11202108519TA (en) 2021-09-29
CA3129067A1 (en) 2020-08-20
JP2022520822A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
SG146624A1 (en) Cytokine inhibitors
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
WO2007146284A3 (en) Thienopyrimidines useful as modulators of ion channels
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
MX2007015740A (es) Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa.
WO2003000194A3 (en) Thienopyridine and thienopyrimidine anticancer agents
TW200716651A (en) Thienopyrimidine and thienopyridine kinase modulators
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2010006025A (es) Analogo de pterina para tratar afeccion sensible a bh4.
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
DE60215139D1 (en) Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
TNSN05291A1 (en) Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
WO2010151815A3 (en) 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
PH12021550557A1 (en) Furo[3,4-b]pyrrole-containing btk inhibitor